IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.940
AS - Asia 5.217
EU - Europa 3.819
SA - Sud America 832
Continente sconosciuto - Info sul continente non disponibili 416
AF - Africa 184
OC - Oceania 19
Totale 18.427
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.614
CN - Cina 2.192
SG - Singapore 1.152
IE - Irlanda 876
HK - Hong Kong 680
BR - Brasile 638
VN - Vietnam 574
IT - Italia 465
RU - Federazione Russa 458
DE - Germania 399
FI - Finlandia 391
FR - Francia 315
UA - Ucraina 290
GB - Regno Unito 182
SE - Svezia 155
CA - Canada 153
IN - India 112
BD - Bangladesh 101
MX - Messico 68
ZA - Sudafrica 68
AR - Argentina 67
NL - Olanda 48
IQ - Iraq 45
AT - Austria 44
PK - Pakistan 43
TR - Turchia 40
PL - Polonia 38
CO - Colombia 34
ID - Indonesia 34
JP - Giappone 34
RO - Romania 29
MY - Malesia 28
MA - Marocco 27
ES - Italia 25
VE - Venezuela 24
SA - Arabia Saudita 23
EC - Ecuador 22
UZ - Uzbekistan 18
AU - Australia 17
CR - Costa Rica 17
JO - Giordania 17
PY - Paraguay 17
CL - Cile 16
JM - Giamaica 16
EG - Egitto 15
PH - Filippine 15
BE - Belgio 14
KE - Kenya 14
NI - Nicaragua 14
AE - Emirati Arabi Uniti 13
LT - Lituania 12
CZ - Repubblica Ceca 11
IL - Israele 11
TN - Tunisia 11
HN - Honduras 10
NP - Nepal 10
AZ - Azerbaigian 9
EE - Estonia 9
KZ - Kazakistan 8
PR - Porto Rico 8
TT - Trinidad e Tobago 8
DZ - Algeria 7
EU - Europa 7
GT - Guatemala 7
LB - Libano 7
MU - Mauritius 7
AL - Albania 6
CH - Svizzera 6
OM - Oman 6
UY - Uruguay 6
CW - ???statistics.table.value.countryCode.CW??? 5
ET - Etiopia 5
GR - Grecia 5
KG - Kirghizistan 5
KR - Corea 5
LA - Repubblica Popolare Democratica del Laos 5
LV - Lettonia 5
PA - Panama 5
PT - Portogallo 5
RS - Serbia 5
SC - Seychelles 5
TH - Thailandia 5
AM - Armenia 4
DK - Danimarca 4
GD - Grenada 4
LK - Sri Lanka 4
NG - Nigeria 4
PE - Perù 4
QA - Qatar 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GP - Guadalupe 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
Totale 17.978
Salva come PNG Salva come JPEG
Città #
Dublin 873
San Jose 839
Ashburn 700
Hong Kong 665
Chandler 644
Singapore 560
Dallas 552
Council Bluffs 470
Jacksonville 428
Nanjing 394
Beijing 388
Boardman 262
Lauterbourg 242
Los Angeles 197
Ho Chi Minh City 196
New York 169
Princeton 167
Nanchang 164
Lawrence 158
Helsinki 138
Hanoi 123
Wilmington 121
Shenyang 118
Changsha 116
Hebei 110
Santa Clara 106
Medford 103
Munich 97
Jiaxing 91
Shanghai 85
Buffalo 83
Ann Arbor 79
Tianjin 77
Moscow 69
Hangzhou 63
Redondo Beach 63
Milan 62
São Paulo 56
Johannesburg 53
Orem 45
Pavia 41
Toronto 41
Rome 40
Nuremberg 39
Seattle 37
Columbus 36
Brooklyn 34
Da Nang 34
Denver 34
Turku 34
Montreal 33
Woodbridge 31
Frankfurt am Main 30
Norwalk 30
Tokyo 30
Haiphong 29
Warsaw 29
San Francisco 27
Atlanta 26
Chennai 25
Chicago 24
Falkenstein 24
Houston 24
Mexico City 24
Washington 24
Boston 23
Stockholm 22
The Dalles 22
Timisoara 22
Vienna 20
London 19
Phoenix 19
Guangzhou 18
North Bergen 18
Rio de Janeiro 18
Florence 17
Fairfield 16
Verona 16
Amman 15
Baghdad 15
Hải Dương 15
Manchester 15
Tashkent 15
Brussels 14
Charlotte 14
Jinan 14
Poplar 14
Zhengzhou 14
Curitiba 13
Managua 13
Queens 13
Rawalpindi 13
Buenos Aires 12
Catania 12
Naples 12
Ankara 11
Brasília 11
Kuala Lumpur 11
Auburn Hills 10
Belo Horizonte 10
Totale 11.242
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 200
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 193
An insidious presentation of splenic marginal zone lymphoma 165
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 160
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 160
Blast phase of essential thrombocythemia: A single center study. 156
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 156
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 154
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 152
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 151
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 150
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 146
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 145
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 143
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 140
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 139
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 139
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 135
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 132
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 130
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 129
Clinical significance of somatic mutation in unexplained blood cytopenia 127
Diagnosis and management of prefibrotic myelofibrosis. 127
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 126
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 126
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 126
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 126
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 124
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 121
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). 121
Somatic mutations of calreticulin in myeloproliferative neoplasms 121
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 120
JAK2 (V617F) mutation in healthy individuals 119
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 119
Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy 119
Allelic imbalance in CALR somatic mutagenesis 117
A journey through infectious risk associated with ruxolitinib. 116
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 115
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 115
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 114
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 113
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 113
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 112
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 112
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 111
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 109
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 109
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 109
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 109
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 108
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 108
Facing erythrocytosis: Results of an international physician survey. 107
Role of the molecular staging and response in the management of follicular lymphoma patients 106
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 106
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 106
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 106
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 105
Clinical relevance of JAK2 (V617F) mutant allele burden 105
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 104
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 104
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 103
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 103
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 103
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 102
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 101
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 101
Cardiovascular events and intensity of treatment in polycythemia vera. 101
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 101
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 101
COVID-19 in Patients with Hematologic Diseases 100
Familial chronic myeloproliferative disorders: the state of the art 100
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 100
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 99
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 99
Peripheral intraneutrophil diplococci in a case of meningococcemia. 99
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. 99
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 99
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms 98
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms 97
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 97
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 97
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 97
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 96
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 96
Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver 95
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 94
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 94
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 93
Mutations and prognosis in primary myelofibrosis 93
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 93
Improving survival trends in primary myelofibrosis: an international study. 93
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 92
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 91
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 91
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 91
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 91
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. 91
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 90
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 90
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 90
Totale 11.497
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.155
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022656 0 0 0 11 17 38 6 38 33 38 115 360
2022/20232.087 222 118 21 135 204 169 1 100 989 13 87 28
2023/20241.049 119 170 55 69 96 297 27 66 10 22 76 42
2024/20252.759 66 208 72 61 56 120 198 204 641 114 370 649
2025/20266.755 497 556 786 788 723 311 1.281 239 587 518 250 219
2026/20271.931 125 446 513 847 0 0 0 0 0 0 0 0
Totale 18.427